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Purpose:  Secondarily  generalized  tonic-clonic  seizures  (SGTCS)  are  among  the  most  devastating  types  of
seizures,  contributing  to increased  morbidity  and  mortality.  Brivaracetam  (BRV),  a  selective,  high-afﬁnity
ligand  for  synaptic  vesicle  2A (SV2A),  has  been  shown  to  be useful  for  the  adjunctive  treatment  of focal
seizures.  We  sought  to  determine  its speciﬁc  efﬁcacy  in treating  SGTCS.
Methods:  Data  were  pooled  from  three  Phase  III studies  (NCT00490035;  NCT00464269;  NCT01261325)
of  adults  with  focal seizures  taking  1–2  antiepileptic  drugs  (AEDs)  who  received  placebo  or
BRV  50–200  mg/day  without  titration  over  a  12-week  treatment  period.  We  report  efﬁcacy  and
safety/tolerability  data  for  the  BRV  therapeutic  dose  range  (50–200  mg/day)  in  patients  with  focal  seizures
including  baseline  SGTCS.
Results:  Patients  (efﬁcacy  population,  N  =  409)  had  been  diagnosed  with  epilepsy  for  a  mean  ±  standard
deviation  duration  of  22.2  ±  13.1  years.  Baseline  median  SGTCS  frequency  was  3.0 per  28  days.
The  majority  (293,  71.6%)  had  failed ≥2  AEDs  prior  to  study  enrollment.  The  median  percent
reduction  from  baseline  in SGTCS  frequency/28  days  was:  placebo,  33.3%;  BRV  50 mg/day,  66.6%
(p  <  0.001);  BRV  100  mg/day,  61.2%  (p =  0.002);  and  BRV  200  mg/day,  82.1%  (p < 0.001).  The  ≥50%
responder  rate  for  SGTCS  was:  placebo,  33.0%;  BRV  50 mg/day,  61.3%  (p = 0.003);  BRV  100  mg/day,
55.0%  (p <  0.001);  and BRV  200  mg/day,  64.0%  (p < 0.001).  Freedom  from  SGTCS  was  achieved  by:
placebo,  14.8%;  BRV  50  mg/day,  22.6%;  BRV  100  mg/day,  31.0%;  and  BRV  200  mg/day,  36.0%  of
patients.  Time  to ﬁrst  SGTCS  during  the  treatment  period  was  longer  in patients  receiving  BRV  than
placebo  (26  days  vs 8 days,  hazard  ratio 0.55,  p < 0.001).  In the  SGTCS  safety  population  (N =  487),
treatment-emergent  adverse  events  (TEAEs)  were  reported  by 60.6%  of patients  receiving placebo
vs  65.0%  of  patients  receiving  BRV  ≥50  mg/day.  Serious  TEAEs  were  reported  by  3.1%  placebo  vs
3.9%  BRV  ≥50 mg/day.  Discontinuations  due  to  TEAEs  were  3.9%  placebo  vs  6.3% BRV  ≥50  mg/day.
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Conclusions:  In patients  with  drug-resistant  focal  seizures,  adjunctive  BRV  is  effective  in  reducing  the
frequency  of SGTCS.  Almost  one-third  (30.4%)  of  patients  were  rendered  completely  free  of SGTCS  during
the  12-week  treatment  period  when  taking  BRV  ≥50  mg/day.  BRV  was well  tolerated,  with  a  TEAE  proﬁle
consistent  with  that  of  the  overall  study  population.
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. Introduction
Patients with drug-resistant focal epilepsy are at increased risk
or a number of physical and psychosocial complications. Such
isks are heightened when their uncontrolled seizures secondarily
eneralize. Given the increased risk of falls associated with general-
zed tonic-clonic seizures (GTCS), such seizures carry a 2.9 relative
isk for injuries, in a univariate regression analysis adjusted for
eizure frequency (Lawn et al., 2004). GTCS also increase the risk
f associated head trauma (Beghi, 2009; Nakken and Lossius, 1993;
eufeld et al., 1999) and fractures (Persson et al., 2002). In addi-
ion, lower quality of life (QOL) has been observed in patients with
TCS. This is captured by poorer scores relating to work/social
unction, energy/fatigue, health discouragement, emotional well-
eing, seizure worry, social isolation, health perception, bodily
ains, social support, overall health, and overall QOL (Shetty et al.,
011; Viteva, 2014). After adjusting for individual psychological
omorbidities, seizure severity has been shown to be the strongest
redictor of psychosocial variables including anxiety, self-esteem,
nd locus of control (Smith et al., 1991). Most importantly, GTCS
re known to increase the risk of mortality, with a hazard ratio
pproaching 6.2 in a patient population newly diagnosed with
pilepsy (Lhatoo et al., 2001). Intractable convulsive seizures are
egarded as one of the strongest risk factors for sudden unex-
ected death in epilepsy (SUDEP) (Devinsky, 2011; Hirsch et al.,
011; Laxer et al., 2014; Shorvon and Tomson, 2011). This has
esulted in such seizures being included in historical risk fac-
or inventories for this dreaded phenomenon (DeGiorgio et al.,
010).
When patients with drug-resistant focal seizures are not can-
idates for resective epilepsy surgery, physicians often rely on
ewer antiepileptic drugs (AEDs) to try and improve seizure con-
rol. One of the latest AEDs to be approved for adjunctive treatment
f focal seizures is brivaracetam (BRV). BRV is a synaptic vesi-
le 2A (SV2A) ligand, with a 10- to 30-fold increased afﬁnity for
V2A compared to levetiracetam (Gillard et al., 2011; Kenda et al.,
004; Malykh and Sadaie, 2010). In three Phase III clinical tri-
ls, adjunctive therapy with BRV at doses ranging from 50 to
00 mg/day signiﬁcantly reduced the frequency of focal seizures
Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014). Given
ts mechanism of action, no requirement to titrate, and over-
ll tolerability, BRV is a potentially useful treatment for patients
ith drug-resistant focal seizures. However, the speciﬁc efﬁcacy
f BRV in reducing secondarily generalized tonic-clonic seizures
SGTCS) has not been robustly explored. Although the results
f the individual Phase III trials suggested efﬁcacy for SGTCS,
hey were not powered to detect signiﬁcant differences in reduc-
ions of speciﬁc seizure subtypes. A pooled analysis is needed to
ore deﬁnitively determine the effectiveness of BRV at different
herapeutic doses in reducing the frequency of these debilitating
eizures.
Given the increased morbidity and mortality associated with
GTCS, we performed a post-hoc analysis of pooled Phase III clinical
rial data on the effects of BRV on this speciﬁc seizure subtype. We
ought to determine the efﬁcacy, safety, and tolerability of BRV in
atients with focal seizures including baseline SGTCS.ium.  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Materials and methods
2.1. Study design
This was a post-hoc analysis of patients with SGTCS among
their baseline seizures from pooled data of three Phase III tri-
als; data for the approved BRV dosages (50–200 mg/day) are
reported. All trials were prospective, multicenter, randomized,
double-blind, placebo-controlled, parallel-group, ﬁxed-dose stud-
ies (NCT00490035, NCT00464269, and NCT01261325). Each study
consisted of an 8-week prospective baseline period and 12-week
treatment period. These were followed by a variable (1- to 4-week)
down-titration and subsequent drug-free period, or entry into an
optional open-label, long-term follow-up study (Biton et al., 2014;
Klein et al., 2015; Ryvlin et al., 2014). At the conclusion of the base-
line period, patients were randomized to receive placebo (PBO) or
BRV (5, 20, 50, 100, or 200 mg/day, dependent on the study) admin-
istered in two equally divided doses without titration. All studies
were conducted in accordance with the International Conference
on Harmonization notes for Guidance on Good Clinical Practice
and the Declaration of Helsinki. All study protocols were approved
by institutional review boards at participating study sites. Written
informed consent was obtained from all patients prior to enroll-
ment. For complete details of individual study design, please refer
to studies NCT00490035, NCT00464269, and NCT01261325 (Biton
et al., 2014; Klein et al., 2015; Ryvlin et al., 2014).
2.2. Study population
Patients aged ≥16–70 years (Biton et al., 2014; Ryvlin et al.,
2014) or aged ≥16–80 years (Klein et al., 2015) were eligible
for study enrollment provided they had well- characterized focal
seizures or a focal epilepsy syndrome. Their focal seizures had
to be uncontrolled despite 1–2 concomitant AEDs at stable and
optimal doses for ≥1 month prior to the ﬁrst study visit. At least
2 focal seizures/month for the 3 months prior to screening and
≥8 focal seizures during the 8-week prospective baseline period
were required for eligibility. In addition, patients were required
to have ≥2 focal seizures in each 4-week interval of the baseline
period in study NCT01261325. For complete inclusion and exclu-
sion criteria, please refer to studies NCT00490035, NCT00464269,
and NCT01261325 (Biton et al., 2014; Klein et al., 2015; Ryvlin
et al., 2014). Patients with SGTCS among their baseline seizures,
whether or not they had other types of seizure, were included in
this post-hoc analysis.
2.3. Efﬁcacy assessments
Seizure occurrence was assessed via patient reporting on daily
record cards. These cards were reviewed by investigators at each
study visit. Outcomes for the current post-hoc analysis included
median percent reduction in SGTCS/28 days, ≥50% and ≥75%
responder rates for SGTCS, freedom from SGTCS, and time to ﬁrst
SGTCS as assessed during the 12-week treatment period. The ≥50%
responder rates for focal seizures without impairment of aware-
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Table  1
Demographics and baseline characteristics of patients with baseline secondary generalized tonic-clonic seizures (efﬁcacy population).
Placebo (n = 115) BRV 50 mg/day (n = 62) BRV 100 mg/day (n = 100) BRV 200 mg/day (n = 75) BRV ≥50 mg/day (n = 237)
Age (years), mean (SD) 35.8 (12.8) 35.3 (12.7) 37.8 (12.3) 38.1 (12.9) 37.2 (12.6)
Female, n (%) 54 (47.0) 29 (46.8) 49 (49.0) 36 (48.0) 114 (48.1)
Race,  white, n (%) 78 (67.8) 46 (74.2) 65 (65.0) 58 (77.3) 169 (71.3)
BMI  (kg/m2), mean (SD) 25.8 (6.1) 24.6 (4.7) 26.9 (6.3) 26.2 (6.6) 26.1 (6.1)
Baseline seizure frequency Focal
Mean (SD)/28 days 16.3 (18.7) 16.7 (22.7) 15.5 (19.4) 22.8 (62.4) 18.1 (39.0)
Median/28 days 9.4 9.3 8.5 7.5 8.3
SGTC
Mean  (SD)/28 days 5.1 (6.1) 5.5 (6.1) 5.2 (6.6) 2.9 (3.2) 4.5 (5.7)
Median/28 days 3.2 3.5 3.0 1.6 2.8
Prior  AEDs, n (%)
0–1 36 (31.3) 22 (35.5) 25 (25.0) 12 (16.0) 59 (24.9)
2–4  42 (36.5) 30 (48.4) 32 (32.0) 30 (40.0) 92 (38.8)
≥5  37 (32.2) 10 (16.1) 43 (43.0) 33 (44.0) 86 (36.3)
Concomitant AEDs, n (%)
1  26 (22.6) 10 (16.1) 19 (19.0) 19 (25.3) 48 (20.3)
2  83 (72.2) 44 (71.0) 72 (72.0) 54 (72.0) 170 (71.7)
 (9.0)
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ED = antiepileptic drug; BMI  = body mass index; BRV = brivaracetam; SD = standard
ess (Type IA) and focal dyscognitive seizures (Type IB) were also
ssessed in patients with baseline SGTCS.
.4. Safety and tolerability assessments
Treatment-emergent adverse events (TEAEs) were recorded at
ach study visit. In addition to being questioned about TEAEs at
ach study visit, patients could spontaneously report TEAEs at any
oint during the treatment period. TEAEs were classiﬁed as mild,
oderate, or severe and whether or not they were attributable to
tudy medication. TEAEs were deemed serious when they resulted
n death, were life-threatening, required hospitalization, resulted
n persistent or signiﬁcant disability/incapacity, or resulted in con-
enital anomalies/birth defects.
.5. Statistical methods
A post-hoc analysis was performed on patients with ≥1 SGTCS
ecorded during the 8-week prospective baseline period who  had
eceived the BRV dosages 50–200 mg/day.
Percent reduction from baseline in SGTCS frequency/28 days
as assessed by Hodges–Lehmann non-parametric effect esti-
ates between BRV treatment groups and placebo. Responder rates
ere evaluated by logistic regression with 28-day adjusted seizure
requency for the treatment period as the outcomes, effects for
reatment and study, and log-transformed baseline seizure fre-
uency as a continuous covariate. Freedom from SGTCS was deﬁned
s no SGTCS being reported over the entire 12-week treatment
eriod for patients who had completed their seizure diaries on all
ays. Time to ﬁrst SGTCS was determined using patient seizure
iary information from the start to the last day study drug was
dministered during the treatment period. Patients who discontin-
ed during the treatment period were censored; the censored date
as based on date of study drug discontinuation. Hazard ratios
nd treatment group comparisons were obtained from a semi-
arametric hazards regression model with number of days to the
rst SGTCS as the outcome and an effect for treatment, and log-
ransformed baseline SGTCS frequency as a continuous covariate.
aplan-Meier survival curves and estimates were generated for the
2-week treatment period. P-values were nominal because of the
xploratory nature of the analysis; the alpha level was  set at 0.05.
Given that BRV doses of 50–200 mg/day are considered ther-
peutic, all efﬁcacy and TEAE analyses were performed for PBO 2 (2.7) 19 (8.0)
tion; SGTC = secondary generalized tonic-clonic.
versus BRV 50–200 mg/day. For all variables examined, results are
separately reported as PBO versus BRV 50, 100, and 200 mg/day.
The safety population comprised all patients who had taken ≥1
dose of study drug and had baseline SGTCS. The efﬁcacy population
comprised all patients from the primary efﬁcacy analyses who  had
baseline SGTCS. Patients receiving concomitant levetiracetam (LEV)
were excluded (Biton et al., 2014; Ryvlin et al., 2014) for consistency
with the trial which did not include patients taking concomitant
LEV (Klein et al., 2015).
3. Results
3.1. Patient demographics and baseline characteristics
A total of 409 subjects with baseline histories of SGTCS com-
prised the efﬁcacy population [222 men  (54.3%) and 187 women
(45.7%)]. The average age ± standard deviation (SD) at study enroll-
ment was  36.4 ± 12.6 years. The mean ± SD duration of epilepsy
of all participants in the efﬁcacy population was  22.2 ± 13.1 years.
The majority (293, 71.6%) of participants had failed ≥2 AEDs prior
to randomization. The baseline median SGTCS frequency/28 days
was 3.0 seizures. For a complete listing of all patient demograph-
ics of subjects with baseline histories of SGTCS receiving PBO and
therapeutic doses of BRV, see Table 1.
3.2. Efﬁcacy for SGTCS
Median percent reduction from baseline in SGTCS fre-
quency/28 days during the treatment period varied by daily BRV
dosage. This included a median percent reduction in SGTCS of 66.6%
for 50 mg/day (n = 62, p < 0.001), 61.2% for 100 mg/day (n = 100,
p = 0.002), and 82.1% for 200 mg/day (n = 75, p < 0.001) versus 33.3%
for PBO (n = 115, see Table 2). This indicates that median SGTCS fre-
quencies were reduced from baseline to 2.1 (PBO) versus 1.2, 1.2,
and 0.3 SGTCS/28 days for BRV 50, 100, and 200 mg/day, respec-
tively.
Doses of BRV ≥50 mg/day were associated with a signiﬁcantly
greater ≥50% responder rate than PBO (141/237, 59.5% vs 38/115,
33.0%, p < 0.0001). This difference remained signiﬁcant for individ-
ual BRV doses of 50 mg/day (38/62, 61.3%, p = 0.003), 100 mg/day
(55/100, 55.0%, p < 0.001), and 200 mg/day (48/75, 64%, p < 0.001,
see Fig. 1). Therapeutic doses of BRV were also associated with a
signiﬁcantly greater ≥75% responder rate than PBO (106/237, 44.7%
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Table 2
Median percent reduction from baseline in secondary generalized tonic-clonic seizures/28 days during the 12-week treatment period (efﬁcacy population).
Placebo
(n = 115)
BRV 50 mg/day
(n = 62)
BRV 100 mg/day
(n = 100)
BRV 200 mg/day
(n = 75)
BRV ≥50 mg/day
(n = 237)
Median percent reduction from
baseline in SGTCS/28 days
33.3 66.6 61.2 82.1 67.5
Median difference vs placebo
95% CI (LL, UL)
28.4
(11.0, 45.0)
25.1
(6.0, 43.6)
38.9
(16.1, 53.1)
29.4
(14.6, 43.8)
P-value  <0.001 
BRV = brivaracetam; CI = conﬁdence interval; LL = lower limit; SGTCS = secondary generali
Fig. 1. ≥50% and ≥75% responder rates for secondary generalized tonic-clonic
seizures during the 12-week treatment period (efﬁcacy population).
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2013; Sperling et al., 2016). GTCS are associated with worsened-values are versus placebo.
s 25/115, 21.7%, p < 0.001). Although the ≥75% responder rate for
RV 50 mg/day did not reach statistical signiﬁcance (22/62, 35.5%,
 = 0.152), it was signiﬁcant for daily doses of 100 mg  (44/100,
4.0%, p < 0.001) and 200 mg  (40/75, 53.3%, p < 0.001, see Fig. 1).
Complete freedom from SGTCS in those with SGTCS during the
aseline period was achieved by 17/115 patients (14.8%) receiving
BO versus 72/237 patients (30.4%; p = 0.001) receiving therapeu-
ic doses of BRV during the 12-week treatment period. Complete
GTCS freedom rates increased in a dose-dependent fashion as the
ose of BRV increased from 50 mg/day (14/62, 22.6%) to 100 mg/day
31/100, 31.0%) to 200 mg/day (27/75, 36.0%, see Fig. 2). Further-
ore, low incidences of new-onset SGTCS during the treatment
eriod were seen in patients treated with placebo (8/303) and BRV
0 mg/day, 100 mg/day and 200/mg day (8/99, 6/232 and 0/174,
espectively) who were free from SGTCS during the 8-week base-
ine period (Klein et al., 2015).
Receiving therapeutic doses of BRV resulted in a signiﬁcantly
onger time to ﬁrst SGTCS during the treatment period than PBO
26 vs 8 days, hazard ratio 0.55, 95% conﬁdence interval 0.42, 0.71,
 < 0.001). This remained signiﬁcant when the individual therapeu-
ic doses ranging from 50 to 200 mg/day were examined (Table 3).
ased on Kaplan-Meier estimates of the percentage of patients
ompleting speciﬁed durations of treatment (Fig. 3), 32.9% of
atients receiving therapeutic doses of BRV remained free of SGTCS
or 12 weeks versus 15.0% of those receiving PBO (see Supplemental
able S1).
In patients with baseline SGTCS, reductions in other types of
ocal seizures without secondary generalization (with or with-
ut impairment of consciousness) was generally greater than PBO.
nformation regarding ≥50% responder rates for focal seizures
ithout impairment of awareness and focal dyscognitive seizures0.002 <0.001 <0.001
zed tonic-clonic seizure; UL = upper limit.
in those with baseline SGTCS is presented in Supplemental Tables
S2 and S3.
3.3. Safety and tolerability
A total of 487 subjects with baseline histories of SGTCS com-
prised the safety population. The numbers of patients reporting
TEAEs were similar between those patients receiving PBO (77/127,
60.6%) and those receiving BRV ≥50 mg/day (165/254, 65.0%).
Drug-related TEAEs were recorded in 100/254 patients (39.4%)
receiving BRV ≥50 mg/day (vs 41/127, 32.3% receiving PBO). Serious
TEAEs were reported by 10/254 patients (3.9%) receiving thera-
peutic doses of BRV, and were considered by the investigator to
be drug-related in 3 (1.2%) patients. This is similar to the 4/127
patients (3.1%) receiving PBO who reported serious TEAEs, and
were considered to be drug-related in 1 (0.8%) patient. Study med-
ication discontinuation secondary to TEAEs occurred in 16/254
patients (6.3%) receiving BRV ≥50 mg/day versus 5/127 patients
(3.9%) receiving PBO. The most commonly reported side effects
in those receiving therapeutic doses of BRV included somnolence
(12.6%), headache (11.0%), dizziness (8.3%), fatigue (7.9%), and nau-
sea (5.9%). Such safety and tolerability data in the SGTCS safety
population were consistent with corresponding data from the
pooled Phase III studies examining all focal seizure subtypes (Ben-
Menachem et al., 2016).
During the three Phase III trials, four patients with baseline his-
tory of SGTCS died. One patient was in the PBO group, two  were
randomized to BRV 200 mg/day and one was randomized to BRV
50 mg/day. All deaths in the BRV-treated patients were classiﬁed as
SUDEP and occurred 1–14 days following the last conﬁrmed dose
of BRV.
4. Discussion
The results of this analysis indicate that adjunctive treatment
with BRV appears to be effective in reducing the frequency of
SGTCS with an indication of dose-dependence. Patients treated
with doses of BRV ranging from 50 to 200 mg/day without titra-
tion were signiﬁcantly more likely to achieve a ≥50% reduction in
the frequency of this severe seizure subtype compared with those
treated with PBO. The efﬁcacy of BRV in reducing the frequency
of SGTCS was demonstrated at multiple endpoints, and nearly one-
third of patients achieved freedom from SGTCS during the 12-week
treatment period. Such efﬁcacy in reducing SGTCS was not associ-
ated with higher rates of TEAEs than those reported in the overall
study population with focal seizures.
The ability of SGTCS reduction to improve the overall health and
QOL of patients with drug-resistant focal epilepsy cannot be over-
stated. Even when complete seizure freedom is not achievable, a
meaningful reduction in SGTCS has the potential to improve the life
expectancy, health, and QOL of patients (Moschetta and Valente,memory function (Witt and Helmstaedter, 2012), and frequency of
GTCS is linked to cognitive decline (Thompson and Duncan, 2005).
Conversely, periods of remission have been associated with better
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Fig. 2. Complete freedom from secondary generalized tonic-clonic seizures during the 12-week treatment period (efﬁcacy population).
Table 3
Time to onset of ﬁrst secondary generalized tonic-clonic seizures during the 12-week treatment period (efﬁcacy population).
Placebo (n = 115) BRV 50 mg/day (n = 62) BRV 100 mg/day (n = 100) BRV 200 mg/day (n = 75) BRV ≥50 mg/day (n = 237)
Time to ﬁrst seizure, median (days) 8 23 17 56 26
95%  CI (LL, UL) (0.39, 0.79) (0.43, 0.80) (0.34, 0.71) (0.42, 0.71)
P-value  0.001 <0.001 <0.001 <0.001
BRV = brivaracetam; CI = conﬁdence interval; LL = lower limit; UL = upper limit.
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ognitive outcomes (Thompson and Duncan, 2005). Equally impor-
ant, a reduction in SGTCS may  help to reduce seizure-related injury
nd death. Continued GTCS are associated with a >10-fold increase
n the rate of minor injuries, with an almost 3-fold increase in the
ate of severe injuries versus healthy controls (Asadi-Pooya et al.,
012). In a study of resective epilepsy surgery outcomes, it was
bserved that signiﬁcant palliation of SGTCS was a worthwhile goal,
ven when complete seizure freedom was not achievable. Reduc-
ng the occurrence of SGTCS to ≤2 per year was associated with a
igniﬁcant reduction in mortality, comparable to that of seizure-
ree patients (Sperling et al., 2016). Population-based studies have
hown that decreasing GTCS frequency from >3/year to 1–3/year
ay  be associated with a greater than 3-fold decrease in the odds
f dying from SUDEP (Sperling et al., 2016; Walczak et al., 2001).
hen resective epilepsy surgery is not possible or unsuccessful,
hysicians will endeavor to explore newer pharmacologic options
o gain the best control of drug-resistant SGTCS possible. Treatment
ith BRV 50–200 mg/day for 12 weeks resulted in signiﬁcant reduc-ion in the mean number of GTCS versus PBO in the current analysis,
lthough the ﬁnal numbers exceed the goal of 2 or 3 GTCS or fewer
er year, which appears to be associated with reduced mortality
Sperling et al., 2016; Walczak et al., 2001). However, since GTCSnic-clonic seizure during the 12-week treatment period (efﬁcacy population).
are linked to falls, head injuries, and other trauma, any reduction is
likely to lead to reduced morbidity if not mortality.
In various experimental animal models of epilepsy, BRV has
been demonstrated to have higher potency and efﬁcacy than LEV as
both an anti-seizure and anti-epileptogenic agent (Matagne et al.,
2008). However, the anti-epileptogenic effects have not yet been
studied in other clinically relevant animal models or human sub-
jects and hence, data are yet to be translated to show clinical
signiﬁcance. A direct comparison of BRV and LEV on SGTCS con-
trol in humans has not been performed. However, review of Phase
III data yields interesting results. In a post-hoc analysis of pooled
data from three Phase III trials, daily doses of LEV ranging from
1000 to 3000 mg  were found to result in a 68.5% median reduction
from baseline in SGTCS (Leppik et al., 2003). The efﬁcacy of BRV
and LEV in signiﬁcantly reducing SGTCS suggests that SV2A may
be an effective target when attempting to reduce seizure propa-
gation/generalization. This may  be secondary to the widespread
expression of SV2A in the brain. This includes sites such as the
dentate gyrus, entorhinal cortex, frontal cortex, several thalamic
nuclei, and mesencephalon (Douaud et al., 2011; Fuks et al., 2003;
Hanaya et al., 2012), which are often essential for seizure generation
or propagation (Milton and Jung, 2003). Previous models of both
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ocal and generalized seizures have suggested that the SV2A protein
s essential for neuronal synchronization (Kaminski et al., 2008).
iven that BRV has a 10- to 30-fold increased afﬁnity for SV2A vs
EV (Kenda et al., 2004; Malykh and Sadaie, 2010), this new AED
ay  represent a superior way to exploit this speciﬁc antiepileptic
echanism of action.
As with some other newer AEDs, BRV appears to be a useful
herapeutic option to reduce the frequency of SGTCS. At approved
oses of 200 and 400 mg/day, lacosamide has been demonstrated to
educe SGTCS per 28 days from baseline by a median of 50.0–55.6%
s 32.5% for placebo. Higher reductions in SGTCS of 85.9% were
nly reported when lacosamide doses of 600 mg/day (which exceed
he maximum FDA approved daily dose) but were administered
nder the supervision of the investigators in the course of these
ivotal clinical trials (Sperling et al., 2014). Based on data pooled
rom three pivotal trials, the ≥50% responder rate for lacosamide
as been reported as 50.9% (200 mg/day), 53.5% (400 mg/day), and
4.7% (600 mg/day) vs 36.6% (PBO) (Sperling et al., 2014). In a
ooled analysis of three Phase III trials examining its efﬁcacy for
ocal seizures, perampanel was associated with median percent
eductions in SGTCS of 48.6% (4 mg/day), 62.9% (8 mg/day), and
3.3% (12 mg/day) vs 19.4% for PBO (Ko and Ramsay, 2013). The
50% responder rate for SGTCS was 49.3%, 60.5%, and 53.7% for
erampanel 4 mg/day, 8 mg/day, and 12 mg/day, respectively, and
7.0% for PBO (Ko and Ramsay, 2013). In a secondary analysis of
ne pivotal Phase III study, eslicarbazepine acetate (ESL) resulted
n an overall reduction in the median number of SGTCS during the
2-week maintenance period. This included a reduction from 1.5
o 1.2 in the ESL 1200 mg/day group, from 2.5 to 0.9 in the ESL
00 mg/day group, and from 3.2 to 2.7 in the ESL 400 mg/day group
vs 2.5–1.8 in the PBO group) (Elger et al., 2009). Such comparisons
llustrate that SV2A binding appears to have comparable efﬁcacy
o other mechanisms of action, including sodium channel inactiva-
ion and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AMPA) receptor antagonism, in reducing the secondary general-
zation of focal seizures. Unfortunately, data regarding the efﬁcacy
f other AEDs such as clonazepam and ezogabine for SGTCS in sim-
larly designed phase III trials is not readily available.
Our study is not without limitations. These data represent a
ost-hoc analysis of pooled data from three Phase III trials exam-
ning the efﬁcacy of BRV on all focal onset seizure subtypes. The
ndividual studies were powered to detect signiﬁcant differences
n focal onset seizures aggregately, not speciﬁc seizure subtypes.
ith a larger overall sample size of patients with baseline SGTCS,
t is possible that trends in overall median percentage reductions
n SGTCS in those receiving therapeutic doses of BRV would have
eached statistical signiﬁcance. A larger sample size would have
lso potentially permitted statistical analysis of data from patients
ho achieved complete freedom from SGTCS. Furthermore, long
erm efﬁcacy and safety data in this population were not exam-
ned in this post-hoc analysis. Despite the smaller sample size, the
ost-hoc analysis was still able to demonstrate signiﬁcantly larger
ercentages of patients achieving ≥50% reductions in SGTCS. Given
he potential for such meaningful reductions to improve the overall
ealth and QOL of those living with refractory SGTCS, these ﬁndings
eserve notice.
. Conclusions
BRV appears to be effective in reducing the frequency of SGTCS in
 dose-dependent manner. Such results support the adjunctive use
f BRV to treat uncontrolled SGTCS. These results hint at the effec-
iveness of targeting the SV2A as a means of reducing the generation
nd propagation of focal seizures. Given the increased morbidityarch 127 (2016) 179–185
and mortality associated with this seizure subtype, the importance
of such reductions cannot be overemphasized.
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